Loading...
 
Mediterr J Rheumatol 2017; 28(3):116-26
The clinical utility of gene expression examination in rheumatology
Authors Information

Immunology and Molecular Biology Laboratory, Nasonova Research Institute of Rheumatology, Moscow, Russia

References
  1. van Baarsen L G, Bos C L, van der Pouw Kraan T C, Verweij C L. Transcription profiling of rheumatic diseases. Arthritis Res Ther 2009;11:207.
  2. Michaud K. The National Data Bank for Rheumatic Diseases (NDB). Clin Exp Rheumatol 2016;34:S100-S101.
  3. Wang L, Wu L F, Lu X, Mo X B, Tang Z X, et al. Integrated Analyses of Gene Expression Profiles Digs out Common Markers for Rheumatic Diseases. PLoS One 2015;10:e0137522.
  4. Sommer O J, Kladosek A, Weiler V, Czembirek H, Boeck M, Stiskal M. Rheumatoid arthritis: a practical guide to state-of-the-art imaging, image interpretation, and clinical implications. Radiographics 2005;25:381-98.
  5. Firenstein G S, Budd R C, Gabriel S E, McInnes B, O’Dell J R. Kelley’s Textbook of rheumatology, 9th edition, Saunders, Philadelphia, USA, 2013, p.117-431.
  6. Paula F S, Alves J D. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics 2014;8:1-12.
  7. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis 2012;71:1984-90.
  8. van der Helm-van Mil A H M, le Cessie S, van Dongen H, Breedveld F C, Toes R E M, Huizinga T W J. A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007;56:433-40.
  9. Thurlings R M, Boumans M, Tekstra J, van Roon J A, Vos K, van Westing D M, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010;62:3607-14.
  10. Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2016 Dec 24. pii: kew442. https://doi.org/10.1093/rheumatology/kew442. [Epub ahead of print]
  11. Vivar N, Van Vollenhoven R F. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep 2014;6:31.
  12. MacNeil L T, Walhout A J. Gene regulatory networks and the role of robustness and stochasticity in the control of gene expression. Genome Res 2011;21:645-57.
  13. Maksymowych W P, Landewe R, Boers M, Garnero P, Geusens P, El-Gabalawy H, et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. J Rheumatol 2007;34:634-40.
  14. Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014;27:1-10.
  15. Higgs B W, Zhu W, Richman L, Fiorentino D F, Greenberg S A, Jallal B, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012;15:25-35.
  16. Olsen N J, Moore J H, Aune T M. Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells. Arthritis Res Ther 2004;6:120-8.
  17. van Baarsen L G, Wijbrandts C A, Gerlag D M, Rustenburg F, van der Pouw Kraan T C, Dijkmans B A, et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010;11:622-9.
  18. Rustenburg F, Baggen J M, Verweij C L, Rustenburg F, Baggen J M, Verweij C L, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008;67:563-6.
  19. Kim T H, Choi S J, Lee Y H, Song G G, Ji J D. Gene expression profile predicting the response to anti-TNF treatment in patients with rheumatoid arthritis; analysis of GEO datasets. Joint Bone Spine 2014;81:325-30.
  20. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun 2009;387:261-5.
  21. Tchetina E V, Demidova N V, Karateev D E. Positive correlation of ULK1 and MMP-9 versus negative correlation of mTOR and TNFα baseline gene expressions in the peripheral blood with the disease activity and joint destruction indices registered in rheumatoid arthritic patients after treatment. Ann Rheum Dis 2014;73:882. https://doi.org/10.1136/annrheumdis-2014-eular.3992.
  22. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008;47:780-8.
  23. Meugnier E, Coury F, Tebib J, Ferraro-Peyret C, Rome S, Bienvenu J, et al. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. Physiol Genomics 2011;43:365-71.
  24. van der Pouw Kraan T C, Wijbrandts C A, van Baarsen L G, Voskuyl A E, Rustenburg F, Baggen J M, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14.
  25. Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert P E, Hot A, et al. Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 2011;6:e24828.
  26. Cantaert T, van Baarsen L G, Wijbrandts C A, Thurlings R M, van de Sande M G, Bos C, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010;49:156-66.
  27. Crow M K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010;12:S5.
  28. Van Baarsen L G, Wijbrandts C A, Rustenburg F, Cantaert T, van der Pouw Kraan T C, Baeten D L, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11.
  29. Smiljanovic B, Grün J R, Biesen R, Schulte-Wrede U, Baumgrass R, Stuhlmüller B, et al. The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) 2012;90:1295-309.
  30. Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol 2014;66:15-23.
  31. Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray.Arthritis Rheumatol 2014;66:1421-31.
  32. Mitani Y, Takaoka A, Kim SH, Kato Y, Yokochi T, Tanaka N, et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 2001;6:631-40.
  33. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis 2012;71:1583-5.
  34. Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon H J, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol 2014;66:2015-25.
  35. Seyler T M, Park Y W, Takemura S, Bram R J, Kurtin P J, Goronzy J J, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115:3083-92.
  36. Baccala R, Kono D H, Theofilopoulos A N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005;204:9-26.
  37. Tak P P. IFN-β in rheumatoid arthritis. Front Biosci 2004;1:3242-7.
  38. Lequerré T, Bansard C, Vittecoq O, Derambure C, Hiron M, Daveau M, et al. Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia. Arthritis Res Ther 2009;11:R99.
  39. Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, Yamamoto H, Takubo N, et al. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther 2005;7:R825-36.
  40. Frangou E A, Bertsias G K, Boumpas D T. Gene expression and regulation in systemic lupus erythematosus. Eur J Clin Invest 2013;43:1084-96.
  41. Kalunian K C, Merrill J T, Maciuca R, McBride J M, Townsend M J, Wei X, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202.
  42. Hall J C, Baer A N, Shah A A, Criswell L A, Shiboski C H, Rosen A, et al. Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. Arthritis Rheumatol 2015;67:2437-46.
  43. Russell I J, Michalek J E, Kang Y K, Richards A B. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. J Interferon Cytokine Res 1999;19:961-8.
  44. Oliveira T L, Caetano A Z, Belem J M, Klemz B C, Pinheiro M M. Interferon-α induced psoriatic arthritis and autoimmune hemolytic anemia during chronic hepatitis C treatment. Acta Reumatol Port 2014;39:327-30.
  45. Chen W, Foo S S, Li R W, Smith P N, Mahalingam S. Osteoblasts from osteoarthritis patients show enhanced susceptibility to Ross River virus infection associated with delayed type I interferon responses. Virol J 2014;11:189.
  46. Redlich K, Smolen J S. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012;11:234-50.
  47. Baum R, Gravallese E M. Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep 2014;12:9-16.
  48. Tweehuysen L, van den Ende C H, Beeren F M, Been E M, van den Hoogen F H, den Broeder A A. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis Rheumatol 2017;69:301-8.
  49. Landewé R, Smolen J S, Florentinus S, Chen S, Guérette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther 2015;17:133.
  50. Pettit A R, Ji H, von Stechow D, Müller R, Goldring S R, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
  51. Aletaha D, Funovits J, Smolen J S. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis 2011;70:733-9.
  52. Hetland M L, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik A G, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
  53. Tobón G, Saraux A, Lukas C, Gandjbakhch F, Gottenberg J E, Mariette X, et al. First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. Arthritis Care Res (Hoboken) 2013;65:1907-15.
  54. Smolen J S, Han C, van der Heijde D M, Emery P, Bathon J M, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
  55. Scott D L. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000;39:24-9.
  56. Walsh D A, Mapp P I, Kelly S. Calcitonin gene-related peptide in the joint: contributions to pain and inflammation. Br J Clin Pharmacol 2015;80:965-78. 
  57. Brown A K, Conaghan P G, Karim Z, Quinn M A, Ikeda K, Peterfy C G, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
  58. Gärtner M, Sigmund I K, Alasti F, Supp G, Radner H, Machold K, et al. Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. RMD Open 2016;2:e000241.
  59. Døhn U M, Ejbjerg B, Boonen A, Hetland M L, Hansen M S, Knudsen L S, et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8.
  60. Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Schett G. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 2013;72:396-400.
  61. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 2005;95:445-53.
  62. Walsh N C, Reinwald S, Manning CA, Condon K W, Iwata K, Burr D B, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009;24:1572-85.
  63. Matzelle M M, Gallant M A, Condon K W, Walsh N C, Manning C A, Stein G S, et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 2012;64:1540-50.
  64. Danks L, Komatsu N, Guerrini M M, Sawa S, Armaka M, Kollias G, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis 2016;75:1187-95.
  65. Gravallese E M, Harada Y, Wang J T, Gorn A H, Thornhill T S, Goldring S R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
  66. Ruscitti P, Cipriani P, Carubbi F, Liakouli V, Zazzeroni F, Di Benedetto P, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm 2015;2015:782382.
  67. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross F P, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
  68. Smolen J S, Han C, Bala M, Maini R N, Kalden J R, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
  69. Dickerson T  J, Suzuki E, Stanecki C, Shin HS, Qui H, Adamopoulos I E. Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.J Autoimmun 2012;39:369-76.
  70. Cohen S B, Dore R K, Lane N E, Ory P A, Peterfy C G, Sharp J T, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309.
  71. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-99.
  72. Luyten F P, Lories R J, Verschueren P, de Vlam K, Westhovens R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:829-48.
  73. Cunnane G, FitzGerald O, Hummel K M, Youssef P P, Gay R E, Gay S, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001;44:1744-53.
  74. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005;57:973-93.
  75. Hao L, Zhu G, Lu Y, Wang M, Jules J, Zhou X, et al. Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role. FEBS Lett 2015;589:1331-9.
  76. Burrage P S, Mix K S, Brinckerhoff C E. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
  77. Itoh Y. Metalloproteinases: potential therapeutic targets for rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets 2015;15:216-22.
  78. Tchetverikov I, Ronday H K, Van El B, Kiers G H, Verzijl N, TeKoppele J M, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:881-3.
  79. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000;275:444-50.
  80. Kim K S, Choi H M, Lee Y A, Choi I A, Lee S H, Hong S J, et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011;31:543-7.
  81. Poole A R, Nelson F, Dahlberg L, Tchetina E, Kobayashi M, Yasuda T, et al. Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp 2003;70:115-23.
  82. Chen C H, Lin K C, Yu D T, Yang C, Huang F, Chen H A, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006;45:414-20.
  83. Peng W J, Yan J W, Wan Y N, Wang B X, Tao J H, Yang G J, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol 2012;32:1409-14.
  84. Tveita A, Rekvig OP, Zykova S N. Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther 2008;10:229.
  85. Hirata S, Tanaka Y. Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score. Nihon Rinsho Meneki Gakkai Kaishi 2016;39:37-41.
  86. Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, et al. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 2006;33:106-10.
  87. Green M J, Gough A K, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:83-8.
  88. Tchetina E V, Demidova N V, Karateev D E, Nasonov E L. Rheumatoid factor positivity is associated with increased joint destruction and up-regulation of matrix metalloproteinase 9 and cathepsin K gene expression in the peripheral blood in rheumatoid arthritis patients treated with methotrexate. Int J Rheumatol 2013;2013:457876.
  89. Tchetina E V, Pivanova A N, Markova G A, Lukina G V, Aleksandrova E N, Aleksankin A P. Rituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain Control. Arthritis 2016;2016:4963950.
  90. Reynolds R J, Cui X, Vaughan L K, Redden D T, Causey Z, Perkins E, et al. Gene expression patterns in peripheral blood cells associated with radiographic severity in African Americans with early rheumatoid arthritis.Rheumatol Int 2013;33:129-37.
  91. Liu Z, Sokka T, Maas K, Olsen N J, Aune T M. Prediction of disease severity in patients with early rheumatoid arthritis by gene expression profiling. Hum Genomics Proteomics 2009;2009:pii:484351.
  92. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas D T, Carmona L, et al. Finalization and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 2011;70:935-42.
  93. Nijs J, Kosek E, Van Oosterwijck J, Meeus M. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician 2012;15:ES205-13.
  94. Daien C I, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open 2017;3:e000404.
  95. Ossipov M H. The perception and endogenous modulation of pain. Scientifica (Cairo) 2012;2012:561761.
  96. Fitzcharles M A, Shir Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis 2011;3:179-90.
  97. Kidd B L, Urban L A. Mechanisms of inflammatory pain.Br J Anaesth 2001;87:3-11.
  98. Treede R D, Jensen T S, Campbell J N, Cruccu G, Dostrovsky J O, Griffin J W, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
  99. Reichling D B, Green P G, Levine J D. The fundamental unit of pain is the cell. Pain 2013;154:S2-9.
  100. Campbell J N, Meyer R A. Mechanisms of neuropathic pain. Neuron 2006;52:77-92.
  101. Akinci A, Al Shaker M, Chang M H, Cheung C W, Danilov A, José Dueñas H, et al. Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitisation component. Int J Clin Pract 2016;70:31-44.
  102. Latremoliere A, Woolf C J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926.
  103. Nijs J, Van Houdenhove B, Oostendorp R A. Recognition of central sensitization in patients with musculoskeletal pain: Application of pain neurophysiology in manual therapy practice. Man Ther 2010;15:135-41.
  104. Omoigui S. The biochemical origin of pain--proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3-a unifying law of pain. Med Hypotheses 2007;69:70-82.
  105. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med 2010;16:1267-76.
  106. Edwards R R, Wasan A D, Bingham C O 3rd, Bathon J, Haythornthwaite J A, Smith M T, et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther 2009;11:R61.
  107. Jakobsson U, Hallberg I R. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002;11:430-43.
  108. Davis M C, Zautra A J, Younger J, Motivala S J, Attrep J, Irwin M R. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 2008;22:24-32.
  109. Lee Y C, Frits M L, Iannaccone C K, Weinblatt M E, Shadick N A, Williams D A, et al. Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheumatol 2014;66:2006-14.
  110. Lee Y C, Chibnik L B, Lu B, Wasan A D, Edwards R R, Fossel A H, et al. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009;11:R160.
  111. Ranzolin A, Brenol JC, Bredemeier M, Guarienti J, Rizzatti M, Feldman D, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794-800.
  112. Geenen R, Van Middendorp H, Bijlsma J W. The impact of stressors on health status and hypothalamic-pituitary-adrenal axis and autonomic nervous system responsiveness in rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:77-97.
  113. Lee Y C, Lu B, Edwards R R, Wasan A D, Nassikas N J, Clauw D J, et al. The role of sleep problems in central pain processing in rheumatoid arthritis. Arthritis Rheum 2013;65:59-68.
  114. Stack R J, van Tuyl L H, Sloots M, van de Stadt L A, Hoogland W, Maat B, et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford) 2014;53:1646-53.
  115. Altawil R, Saevarsdottir S, Wedrén S, Alfredsson L, Klareskog L, Lampa J. Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate. Arthritis Care Res (Hoboken) 2016;68:1061-8.
  116. Lee Y C, Nassikas N J, Clauw D J. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011;13:211.
  117. Woolf C J. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152:S2-15.
  118. Di Franco M, Guzzo M P, Spinelli F R, Atzeni F, Sarzi-Puttini P, Conti F, et al. Pain and systemic lupus erythematosus. Reumatismo 2014;66:33-8.
  119. Malfait A M, Schnitzer T J. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol 2013;9:654-64.
  120. Zois C D, Katsanos K H, Kosmidou M, Tsianos E V. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis 2010;4:115-24.
  121. Yunus M B. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat 2012;2012:584573.
  122. Abdelhamid R E, Sluka K A. ASICs Mediate Pain and Inflammation in Musculoskeletal Diseases. Physiology (Bethesda) 2015;30:449-59.
  123. Westlund K N, Kochukov M Y, Lu Y, McNearney T A. Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior. Mol Pain 2010;6:46.
  124. Yamaga M, Tsuji K, Miyatake K, Yamada J, Abula K, Ju Y J, et al. Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture. PLoS One 2012;7:e49014.
  125. Walsh D A, McWilliams D F, Turley M J, Dixon M R, Fransès R E, Mapp P I, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 2010;49:1852-61.
  126. Barthel C, Yeremenko N, Jacobs R, Schmidt R E, Bernateck M, Zeidler H, et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther 2009;11:R82.
  127. O'Rourke K P, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, et al. High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int 2008;28:979-86.
  128. Richardson D, Pearson R G, Kurian N, Latif M L, Garle M J, Barrett D A, et al. Characterization of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008;10:R43.
  129. Mousa S A, Straub R H, Schäfer M, Stein C. Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 2007;66:871-9.
  130. Louati K, Berenbaum F. Fatigue in chronic inflammation - a link to pain pathways. Arthritis Res Ther 2015;17:254.
  131. Clark A K, Staniland A A, Malcangio M. Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol 2011;12:1707-14.
  132. Chen Y M, Chen H H, Lan J L, Chen D Y. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine 2010;77:366-7.
  133. Clark I A, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation 2016;13:236.
  134. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U. S. A. 2011;108:3731-6.
  135. Kosek E, Altawil R, Kadetoff D, Finn A, Westman M, Le Maître E, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. J Neuroimmunol 2015;280:49-55.
  136. Lisowska B, Maśliński W, Małdyk P, Zabek J, Baranowska E. The role of cytokines in inflammatory response after total knee arthroplasty in patients with rheumatoid arthritis. Rheumatol Int 2008;28:667-71.
  137. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004;31:695-700.
  138. Andersson M L, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol 2013;40:1977-85.
  139. Rifbjerg-Madsen S, Christensen A W, Boesen M, Christensen R, Danneskiold-Samsøe B, Bliddal H, et al. Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open 2014;4:e006058.
  140. Vardeh D, Wang D, Costigan M, Lazarus M, Saper C B, Woolf C J, et al. COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J Clin Invest 2009;119:287-94.
  141. Orhan C E, Onal A, Ulker S. Antihyperalgesic and antiallodynic effect of sirolimus in neuropathic pain and the role of cytokines in this effect. Neurosci Lett 2010;481:17-20.
  142. Yan H, Zhou H F, Hu Y, Pham C T. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J Rheum Dis Treat 2015;1:5.